


# Supplementary File

## Contents

<b>Supplementary Figure 1. PRISMA 2020 flow diagram of the literature search and study selection process.</b> .....	<b>2</b>
<b>Supplementary Figure 2. Timeline of the clinical course following SARS-CoV-2 vaccination.....</b>	<b>3</b>
<b>Supplementary Table 1. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by New-Onset vs Exacerbation .....</b>	<b>3</b>
<b>Supplementary Table 2. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by Latency .....</b>	<b>3</b>
<b>Supplementary Table 3. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by Vaccine Platform.....</b>	<b>4</b>
<b>Supplementary Table 4. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by Evolution to Systemic Lupus Erythematosus .....</b>	<b>4</b>


**Supplementary Figure 1. PRISMA 2020 flow diagram of the literature search and study selection process.**

Records were identified through database searching (PubMed/Medline, Web of Science, Scopus, Cochrane Library) and through reference and citation screening. After deduplication, records were screened by title and abstract, followed by full-text assessment for eligibility. Studies were excluded if they did not report subacute cutaneous lupus erythematosus (SCLE), were not temporally associated with COVID-19 vaccination, or lacked sufficient clinical details. The final included studies consisted of case reports or case series describing new-onset or flaring SCLE temporally associated with COVID-19 vaccination.



**Supplementary Figure 2. Timeline of the clinical course following SARS-CoV-2 vaccination.**

Cutaneous manifestations developed six days after the first dose of BNT162b2, progressed over several weeks, and were diagnosed as subacute cutaneous lupus erythematosus (SCLE). Lesions gradually resolved after systemic corticosteroid therapy, with no progression to systemic lupus erythematosus (SLE) at four-year follow-up.



**Supplementary Table 1. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by New-Onset vs Exacerbation**

	New-Onset (n=15)	Exacerbation (n=4)
Age (years, mean)	50	60
Gender (F/M)	10/5	3/1
History of autoimmune rheumatic disease, n (%)	4 (27)	4 (100)
Time from vaccination to SCLE onset (days, mean)	6 post 1 dose; 20.6 post 2 dose	7.8 post 1 dose; 4 post 2 dose
Vaccine Type, n (%)	mRNA: 13 (87) vector-based: 1 (7) inactivated virus vaccine: 1 (7)	mRNA: 2 (50) vector-based: 2 (50)
SCLE form, n (%)	annular/polycyclic: 8 (53) papulosquamous: 5 (33) annular/polycyclic+papulosquamous: 1 (7) Rowell's syndrome: 1 (7)	annular/polycyclic: 2 (50) papulosquamous: 2 (50)
SLE evolution, n (%)	3 (20)	1 (25)
Rechallenge reported, n (%)	1 (7) well tolerated	3 (75) well tolerated or mild flare

F, female; M, male; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus

**Supplementary Table 2. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by Latency**

	Time from vaccination to onset ≤ 1 week (n=7)	Time from vaccination to onset > 1 week (n=12)
Age (years, mean)	56	50
Gender (F/M)	4/3	9/3
History of autoimmune rheumatic disease, n (%)	4 (57)	4 (33)
Vaccine Type, n (%)	mRNA: 5 (71) vector-based: 2 (29)	mRNA: 10 (83) vector-based: 1 (8) inactivated virus vaccine: 1 (8)
SCLE presentation, n (%)	new-onset: 5 (71) exacerbation: 2 (29)	new-onset: 10 (83) exacerbation: 2 (17)
SCLE form, n (%)	annular/polycyclic: 5 (71) papulosquamous: 1 (14) Rowell's syndrome: 1 (14)	annular/polycyclic: 5 (42) papulosquamous: 6 (50) annular/polycyclic+papulosquamous: 1 (8)
SLE evolution, n (%)	1 (14)	3 (25)
Rechallenge reported, n (%)	2 (29) well tolerated or mild flare	2 (17) well tolerated

F, female; M, male; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus

Supplementary Table 3. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by Vaccine Platform

	mRNA-based (n=15)	Vector-based (n=3)	Inactivated virus vaccine (n=1)
Age (years, mean)	51	61	48
Gender (F/M)	10/5	2/1	1/0
History of autoimmune rheumatic disease, n (%)	6 (40)	2 (67)	0
Time from vaccination to SCLE onset (days, mean)	6.7 post 1 dose; 22.3 post 2 dose	6.3 post 1 dose; 4 post 2 dose	10 post 2 dose
SCLE presentation, n (%)	new-onset: 13 (87) exacerbation: 2 (13)	new-onset: 1 (33) exacerbation: 2 (67)	new-onset: 1 (100)
SCLE form, n (%)	annular/polycyclic: 7 (47) papulosquamous: 6 (40) annular/polycyclic+papulosquamous: 1 (7) Rowell's syndrome: 1 (7)	annular/polycyclic: 2 (67) papulosquamous: 1 (33)	annular/polycyclic: 1 (100)
SLE evolution, n (%)	3 (20)	1 (33)	0
Rechallenge reported, n (%)	3 (20) well tolerated or mild flare	1 (33) well tolerated	Not reported

F, female; M, male; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus

Supplementary Table 4. SCLE Cases After SARS-CoV-2 Vaccination: Stratified by Evolution to Systemic Lupus Erythematosus

	Evolution to SLE (n=4)	No evolution to systemic disease (n=15)
Age (years, mean)	33	57
Gender (F/M)	3/1	10/5
History of autoimmune rheumatic disease, n (%)	1 (25)	7 (47)
Time from vaccination to SCLE onset (days, mean)	6.5 post 1 dose; 14 post 2 dose	6.6 post 1 dose; 19.1 post 2 dose
Vaccine Type, n (%)	mRNA: 3 (75) vector-based: 1 (25)	mRNA: 12 (80) vector-based: 2 (13) inactivated virus vaccine: 1 (7)
SCLE presentation, n (%)	new-onset: 3 (75) exacerbation: 1 (25)	new-onset: 12 (80) exacerbation: 3 (20)
SCLE form, n (%)	annular/polycyclic: 1 (25) papulosquamous: 3 (75)	annular/polycyclic: 9 (60) papulosquamous: 4 (27) annular/polycyclic+papulosquamous: 1 (7) Rowell's syndrome: 1 (7)
Rechallenge reported, n (%)	1 (25) well tolerated	3 (20) well tolerated or mild flare

F, female; M, male; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus